Compare KB Financial Group, Inc. (KB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? KB Financial Group, Inc. trades at $117.53 (market cap $42.79B), while Regeneron Pharmaceuticals Inc trades at $790 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and KB Financial Group, Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| KB | REGN | |
|---|---|---|
Market Cap | $42.79B | $83.19B |
Sector | Financials | Health |
52-Week High | $124.01 | $812.27 |
52-Week Low | $77.50 | $545.94 |
Dividend Yield | 2.6% | 0.47% |
Enterprise Value | — | $77.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $124.01, up 2.22% today, with a bullish technical outlook from moving averages and recent momentum. The stock shows strong fundamentals, with net income margin at 27.82% and a P/E ratio of 11.03, indicating potential undervaluation. Recent earnings beats in Q1 and Q2 2026, alongside positive news coverage on diversification efforts, support investor confidence.
The outlook for KB is positive, driven by earnings growth and strategic expansion into non-banking segments. Risks include volatile cash flow trends and high interest expenses. Analyst consensus is mixed but leans hold, with institutional interest steady. Upside potential exists if profitability trends continue, though macroeconomic factors could pressure performance.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
